Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Methotrexate Stories

2011-11-05 16:10:00

THOUSAND OAKS, Calif. and NEW YORK, Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease Activity Score (DAS) 28 low disease activity (LDA) or clinical remission on combination Enbrel® (etanercept) plus methotrexate (MTX) in Period one and were...

2011-06-21 21:49:13

2 disease-modifying antirheumatic drugs, TNF inhibitors and hydroxychloroquine, are associated with a reduced risk for the development of diabetes in psoriasis and rheumatoid arthritis patients Individuals with systemic inflammatory conditions, such as rheumatoid arthritis (RA) and psoriasis, experience a 1.5 to 2-fold increased rate of cardiovascular disease. Previous research suggests that inflammation and insulin resistance, linked with these conditions, likely accelerate the development...

2011-06-21 21:43:57

In a study that included nearly 14,000 patients with rheumatoid arthritis or psoriasis, the use of certain disease-modifying antirheumatic drugs was found to lower the risk of diabetes, according to a study in the June 22/29 issue of JAMA. Two common systemic inflammatory conditions, rheumatoid arthritis (RA) and psoriasis, predispose patients to insulin resistance and may place patients at risk for diabetes mellitus (DM). The treatment of psoriasis and RA includes disease-modifying...

2011-05-23 08:00:00

FRANKLIN LAKES, N.J., and ALBUQUERQUE, N.M., May 23, 2011 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty diagnostics laboratory that discovers, develops and markets proprietary tests, and Medco Research Institute, LLC -- a wholly-owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS) -- announced today they have started a joint pilot program called NIMBLE [Novel Interventions in Methotrexate Boosts Levels of Effectiveness] designed to help physicians optimize the effectiveness...

2011-05-16 09:00:00

BRUSSELS, May 16, 2011 /PRNewswire/ -- The ACR hybrid score, a new measure of response to RA treatment recently developed by the American College of Rheumatology, demonstrated improved sensitivity compared to traditional ACR responses, according to recently published results in Arthritis Care & Research. Traditional ACR20/50/70 and DAS28 scores were compared to the ACR hybrid score in a post-hoc analysis of the RAPID 1 study, the first clinical trial data to be analyzed using the ACR...

2011-04-26 14:25:05

A clinical trial has sifted out the most effective single-drug chemotherapy regimen for quick-growing but highly curable cancers that arise from the placentas of pregnant women. In the comparison trial for treating low-risk gestational trophoblastic neoplasia (GTN), researchers found that a biweekly dose of dactinomycin had a higher complete response rate than a weekly dose of methotrexate, the more commonly used drug. GTN is a group of rare tumors that involve abnormal growth of cells inside...

2011-04-07 22:10:33

The findings could lead to novel approaches to drug design Slight oscillations lasting just milliseconds have a huge impact on an enzyme's function, according to a new study by Scripps Research Institute scientists. Blocking these movements, without changing the enzyme's overall structure or any of its other properties, renders the enzyme defective in carrying out chemical reactions. The study, published in April 8, 2011 issue of the journal Science, adds to a growing body of evidence...

2011-03-30 17:04:40

The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis. These are the first JIA guidelines endorsed by the ACR, with the goal of broad acceptance within the rheumatology community. Created as a guide for health care providers, the guidelines focus on the initiation and safety monitoring of multiple medications used in the treatment of JIA, including:     * Non-steroidal...

2011-03-08 15:35:49

Combination therapy for rheumatoid arthritis has consistent safety profile A recent trial of rituximab in combination with a tumor necrosis factor (TNF) inhibitor and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) found the safety profile to be consistent with other RA trials with TNF inhibitors. While the trial reported no new safety risks, clear evidence of an efficacy advantage in RA patients receiving the combination therapy was not observed in this study sample....

2011-01-04 14:12:00

Past smoking history does not affect RA patients' response to treatments Patients with early rheumatoid arthritis (RA) who are current smokers were less likely to achieve good response to methotrexate (MTX) and tumor necrosis factor (TNF) inhibitors than those who never smoked. The study by researchers from Sweden also found that RA patients who smoked in the past did not experience a lower response to these therapies. Results of the 10-year study appear in the January 2011 issue of Arthritis...